{"id":42890,"date":"2023-06-06T13:10:53","date_gmt":"2023-06-06T05:10:53","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=42890"},"modified":"2024-03-14T18:10:18","modified_gmt":"2024-03-14T10:10:18","slug":"ez-cap-cy5-firefly-luciferase-mrna-5-moutp-apexbio%e8%b2%a8%e8%99%9fr1010","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=42890","title":{"rendered":"EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP) APExBIO\u8ca8\u865fR1010"},"content":{"rendered":"

EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP) APExBIO\u8ca8\u865fR1010<\/strong><\/span><\/a><\/span><\/p>\n

EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/span><\/strong><\/span><\/p>\n

\u7522\u54c1\u4ecb\u7d39<\/p>\n

EZ Cap\u2122 Cy5 \u87a2\u706b\u87f2\u87a2\u5149\u7d20\u9176 mRNA (5-moUTP) \u4e00\u65e6\u9032\u5165\u6700\u521d\u5f9e\u87a2\u706b\u87f2 Photinus pyralis \u4e2d\u63d0\u53d6\u7684\u7d30\u80de\u5c31\u6703\u8868\u9054\u87a2\u5149\u7d20\u9176\u86cb\u767d\u3002\u8a72\u9176\u50ac\u5316 ATP \u4f9d\u8cf4\u6027 D-\u87a2\u5149\u7d20\u6c27\u5316\u4e26\u5c0e\u81f4\u5728\u7d04 560 nm \u6ce2\u9577\u8655\u7522\u751f\u5316\u5b78\u767c\u5149\u3002\u87a2\u706b\u87f2\u87a2\u5149\u7d20\u9176\u662f\u4e00\u7a2e\u5e38\u7528\u7684\u751f\u7269\u767c\u5149\u5831\u544a\u57fa\u56e0\uff0c\u7528\u65bc\u57fa\u56e0\u8abf\u63a7\u548c\u529f\u80fd\u7814\u7a76\u3002\u9069\u7528\u65bc mRNA \u50b3\u905e( mRNA delivery)\u3001\u7ffb\u8b6f\u6548\u7387(cell viability)\u3001\u7d30\u80de\u6d3b\u529b(cell viability)\u548c\u9ad4\u5167\u6210\u50cf\u7b49\u6aa2\u6e2c\u3002EZ Cap\u2122 Cy5 \u87a2\u706b\u87f2\u87a2\u5149\u7d20\u9176 mRNA (5-moUTP) \u7684\u6fc3\u5ea6\u70ba 1 \u6beb\u514b\/\u6beb\u5347\u3002\u5b83\u7531 EZ Cap\u2122 Reagent AG (3′ OMe)\uff08\u8ca8\u865f B8178\uff09\u5171\u8f49\u9304\u5c01\u7aef\uff0c\u53ef\u9ad8\u6548\u751f\u6210\u5e3d 1 \u7d50\u69cb\u3002 Cap 1 \u7d50\u69cb\u66f4\u9069\u5408\u54fa\u4e73\u52d5\u7269\u7cfb\u7d71\uff0c\u8f49\u9304\u6548\u7387\u9ad8\u65bc Cap 0 \u7d50\u69cb\uff08ARCA \u548c mCap\uff09\u3002 EZ Cap\u2122 Reagent AG (3′ OMe) \u7372\u5f97\u4e86\u50c5\u4ee5\u6b63\u78ba\u65b9\u5411\u63d2\u5165\u7684\u80fd\u529b\uff0c\u5c0e\u81f4\u5f62\u6210\u7684 mRNA \u7684\u7ffb\u8b6f\u6548\u7387\u662f\u4f7f\u7528 EZ Cap\u2122 Reagent AG \u555f\u52d5\u7684 mRNA \u7684\u5169\u500d\u3002\u6dfb\u52a0 5-moUTP (5-Methoxy-UTP) \u548c poly(A) \u5c3e\u5df4\u53ef\u6291\u5236 RNA \u4ecb\u5c0e\u7684\u5148\u5929\u514d\u75ab\u6fc0\u6d3b\u4e26\u589e\u52a0 mRNA \u5728\u9ad4\u5916\u548c\u9ad4\u5167\u7684\u7a69\u5b9a\u6027\u548c\u58fd\u547d\u3002 Poly(A) \u5c3e\u5728\u63d0\u9ad8\u7ffb\u8b6f\u8d77\u59cb\u6548\u7387\u65b9\u9762\u4e5f\u8d77\u8457\u91cd\u8981\u4f5c\u7528\u3002 Cy5 \u662f\u4e00\u7a2e\u5408\u6210\u7684\u7d05\u8272\u87a2\u5149\u67d3\u6599\uff0c\u6700\u5927\u6fc0\u767c\u548c\u767c\u5c04\u6ce2\u9577\u5206\u5225\u70ba 650 nm \u548c 670 nm\u3002 Cy5-UTP \u548c 5-moUTP \u5728\u8f49\u9304\u6642\u4ee5 1:3 \u7684\u6bd4\u4f8b\u4f7f\u7528\u3002\u6309\u6b64\u6bd4\u4f8b\u9032\u884c\u66ff\u63db\u6703\u7522\u751f\u6613\u65bc\u53ef\u8996\u5316\u4e14\u4ecd\u53ef\u5728\u7d30\u80de\u57f9\u990a\u7269\u4e2d\u7ffb\u8b6f\u7684 mRNA\u3002\u7c97\u7565\u5730\u8aaa\uff0c\u7ffb\u8b6f\u6548\u7387\u548c Cy5-UTP \u66ff\u63db\u4e4b\u9593\u5b58\u5728\u53cd\u76f8\u95dc\u3002\u6240\u6709\u7684\u4fee\u6539\u90fd\u662f\u70ba\u4e86\u6a21\u4eff\u4e00\u500b\u5b8c\u5168\u52a0\u5de5\u7684\u6210\u719f mRNA\u3002 EZ Cap\u2122 Cy5 \u87a2\u706b\u87f2\u87a2\u5149\u7d20\u9176 mRNA (5-moUTP) \u662f\u89c0\u5bdf mRNA \u50b3\u905e(mRNA delivery)\u3001\u5b9a\u4f4d(localization)\u3001\u7ffb\u8b6f( translation a)\u548c\u5176\u4ed6\u884c\u70ba\u7684\u7406\u60f3\u7522\u54c1\u3002<\/p>\n

<\/p>\n

\"COA\u6587\u4ef6_\u5de5\u4f5c\u5340\u57df<\/a><\/p>\n\n\n\n\n\n\n\n
mRNA Length<\/td>\n1921 nucleotides<\/td>\n<\/tr>\n
Concentration<\/td>\n1 mg\/mL<\/td>\n<\/tr>\n
Buffer<\/td>\n1 mM Sodium Citrate, pH 6.4<\/td>\nStorage<\/td>\n-40\u00b0C or below<\/td>\n<\/tr>\n
General tips<\/td>\nDissolve it on ice and take care to prevent RNase contamination degradation. Avoid repeated freezing and thawing as much as possible. Do not vortex. For the first time, it is gently centrifuged and divided into several parts for stand-alone use. Use RNase-free reagents and consumables, using appropriate RNase-free technology. It can not be added to the serum-containing medium until it is mixed with the transfection reagent.<\/td>\n<\/tr>\n
Shipping Condition<\/td>\nEvaluation sample solution : ship with dry ice.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/span><\/strong><\/span><\/p>\n

https:\/\/www.apexbt.com<\/a><\/span><\/p>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
R1001-.1<\/td>\nARCA EGFP mRNA<\/td>\nDirect-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n
R1001-5<\/td>\nARCA EGFP mRNA<\/td>\nDirect-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n
R1001-1<\/td>\nARCA EGFP mRNA<\/td>\nDirect-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n
R1005-.1<\/td>\nFirefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\nBetter performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n
R1005-5<\/td>\nFirefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\nBetter performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n
R1005-1<\/td>\nFirefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\nBetter performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n
R1006-.1<\/td>\nSpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\nUsed with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n
R1006-5<\/td>\nSpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\nUsed with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n
R1006-1<\/td>\nSpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\nUsed with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n
R1007-.1<\/td>\nARCA EGFP mRNA (5-moUTP)<\/td>\nNew modification with better performance — direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n
R1007-5<\/td>\nARCA EGFP mRNA (5-moUTP)<\/td>\nNew modification with better performance — direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n
R1007-1<\/td>\nARCA EGFP mRNA (5-moUTP)<\/td>\nNew modification with better performance — direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n
R1008-.1<\/td>\nARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n
R1008-5<\/td>\nARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n
R1008-1<\/td>\nARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n
R1009-.1<\/td>\nARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n
R1009-5<\/td>\nARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n
R1009-1<\/td>\nARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n
R1010-.1<\/td>\nEZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1010-5<\/td>\nEZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1010-1<\/td>\nEZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1011-.1<\/td>\nEZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\nEGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1011-5<\/td>\nEZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\nEGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1011-1<\/td>\nEZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\nEGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1012-.1<\/td>\nFirefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\nBetter performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n
R1012-5<\/td>\nFirefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\nBetter performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n
R1012-1<\/td>\nFirefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\nBetter performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n
R1013-.1<\/td>\nEZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1013-5<\/td>\nEZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1013-1<\/td>\nEZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1015-.1<\/td>\nEZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\nUsed with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n
R1015-5<\/td>\nEZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\nUsed with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n
R1015-1<\/td>\nEZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\nUsed with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n
R1016-.1<\/td>\nEZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\nEGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1016-5<\/td>\nEZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\nEGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1016-1<\/td>\nEZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\nEGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1017-.1<\/td>\nEZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\nmCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1017-5<\/td>\nEZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\nmCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1017-1<\/td>\nEZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\nmCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1018-.1<\/td>\nEZ Cap\u2122 Firefly Luciferase mRNA<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1018-5<\/td>\nEZ Cap\u2122 Firefly Luciferase mRNA<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1018-1<\/td>\nEZ Cap\u2122 Firefly Luciferase mRNA<\/td>\nFirefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1020-.1<\/td>\nEZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\nHuman erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1020-5<\/td>\nEZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\nHuman erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1020-1<\/td>\nEZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\nHuman erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1021-.1<\/td>\nEZ Cap\u2122 Renilla Luc mRNA<\/td>\nRenilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1021-5<\/td>\nEZ Cap\u2122 Renilla Luc mRNA<\/td>\nRenilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1021-1<\/td>\nEZ Cap\u2122 Renilla Luc mRNA<\/td>\nRenilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1022-.1<\/td>\nEZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\nRenilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1022-5<\/td>\nEZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\nRenilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1022-1<\/td>\nEZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\nRenilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1023-.1<\/td>\nEZ Cap\u2122 Human p53 mRNA<\/td>\nHuman p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1023-5<\/td>\nEZ Cap\u2122 Human p53 mRNA<\/td>\nHuman p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1023-1<\/td>\nEZ Cap\u2122 Human p53 mRNA<\/td>\nHuman p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1024-.1<\/td>\nEZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\nHuman p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1024-5<\/td>\nEZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\nHuman p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1024-1<\/td>\nEZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\nHuman p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1025-.1<\/td>\nEZ Cap\u2122 Human PTEN mRNA<\/td>\nHuman PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1025-5<\/td>\nEZ Cap\u2122 Human PTEN mRNA<\/td>\nHuman PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1025-1<\/td>\nEZ Cap\u2122 Human PTEN mRNA<\/td>\nHuman PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n
R1026-.1<\/td>\nEZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\nHuman PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1026-5<\/td>\nEZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\nHuman PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1026-1<\/td>\nEZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\nHuman PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n
R1027-.1<\/td>\nEZ Cap\u2122 OVA mRNA<\/td>\nOvalbumin mRNA with Cap 1 structure, providing higher transcription efficiency<\/td>\n<\/tr>\n
R1027-5<\/td>\nEZ Cap\u2122 OVA mRNA<\/td>\nOvalbumin mRNA with Cap 1 structure, providing higher transcription efficiency<\/td>\n<\/tr>\n
R1027-1<\/td>\nEZ Cap\u2122 OVA mRNA<\/td>\nOvalbumin mRNA with Cap 1 structure, providing higher transcription efficiency<\/td>\n<\/tr>\n
R1028-.1<\/td>\nEZ Cap\u2122 OVA mRNA (5-moUTP)<\/td>\nOvalbumin mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1028-5<\/td>\nEZ Cap\u2122 OVA mRNA (5-moUTP)<\/td>\nOvalbumin mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n
R1028-1<\/td>\nEZ Cap\u2122 OVA mRNA (5-moUTP)<\/td>\nOvalbumin mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP) APExBIO\u8ca8\u865f […]<\/p>\n","protected":false},"author":3,"featured_media":42891,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368],"tags":[5806],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/42890"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42890"}],"version-history":[{"count":5,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/42890\/revisions"}],"predecessor-version":[{"id":48956,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/42890\/revisions\/48956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/42891"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}